None
Quote | CareDx Inc. (NASDAQ:CDNA)
Last: | $15.29 |
---|---|
Change Percent: | -5.24% |
Open: | $15.67 |
Close: | $15.29 |
High: | $15.99 |
Low: | $14.92 |
Volume: | 678,176 |
Last Trade Date Time: | 06/12/2024 03:00:00 am |
News | CareDx Inc. (NASDAQ:CDNA)
Surveillance Monitoring with Both AlloSure Kidney and the AlloView AI-Enabled Risk Prediction Model Improves the Detection of All Types of Allograft Rejection AlloSure Kidney Detected Subclinical Rejection in Clinically Stable Patients and AlloSure Kidney dd-cfDNA Levels were Elevated Pri...
AI-Derived AlloView Results Correlate with Presence and Type of Biopsy Proven Kidney Rejection Longitudinal Monitoring with AlloSure Kidney Enables Earlier Identification of Graft Injury and Assessment of Rejection Treatment KOAR Data Show Kidney Biopsies Informed by AlloSure Dete...
Message Board Posts | CareDx Inc. (NASDAQ:CDNA)
Subject | By | Source | When |
---|---|---|---|
$CDNA short data if anyone is interested | Porterhouse10 | investorshub | 07/04/2023 6:51:12 AM |
MomentumIts gaining | ClayTrader | investorshub | 06/28/2023 8:06:47 AM |
Price trading | stocktrademan | investorshub | 06/26/2023 1:57:02 AM |
$CDNA got some short data | stocktrademan | investorshub | 06/25/2023 12:04:58 PM |
The trading | TREND1 | investorshub | 06/24/2023 10:05:41 PM |
News, Short Squeeze, Breakout and More Instantly...
CareDx Inc. Company Name:
CDNA Stock Symbol:
NASDAQ Market:
Surveillance Monitoring with Both AlloSure Kidney and the AlloView AI-Enabled Risk Prediction Model Improves the Detection of All Types of Allograft Rejection AlloSure Kidney Detected Subclinical Rejection in Clinically Stable Patients and AlloSure Kidney dd-cfDNA Levels were Elevated Pri...
AI-Derived AlloView Results Correlate with Presence and Type of Biopsy Proven Kidney Rejection Longitudinal Monitoring with AlloSure Kidney Enables Earlier Identification of Graft Injury and Assessment of Rejection Treatment KOAR Data Show Kidney Biopsies Informed by AlloSure Dete...
CareDx Reiterates Position that it Does Not Infringe Natera’s ‘544 Patent Injunction Motion has No Impact on CareDx’s Business or Patient and Clinician Access to AlloSure or AlloMap CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused ...